Access
Login/Register
Supplier Login
Processing botanical materials presents challenges in balancing removal of undesirable contaminants, maintaining then integrity of the plant’s inherent multi-component system and medicinal compounds, and protecting the environment during the process. To ensure product quality, Frutarom developed and patented a highly selective technology, called EFLA? HyperPure, to ensure that finished extracts fulfil these requirements. Utilised in the company’s pharma grade plant in Switzerland, the very first U.S.-based run will be completed this month.
The patented technology, developed and used to process botanical raw materials in the company’s Swiss facility, will begin U.S. production in Frutarom Health, USA in North Bergen, New Jersey plant by the mid-November.
“We are very glad to have this environmentally-friendly technology available in the U.S. for the first time,” says Jeffrey Lind, vice president, Health Business. “This increases our production capacity, allows us to respond more quickly to our customers’ demands, and as with all of our New Jersey-produced ingredients, we now have kosher certified ELFA with a shorter time to market.”
HyperPure has been proven safe and effective. It utilises a cross flow membrane microfiltration process to separate unwanted lipophilic compounds. Stable, pure and active extracts are obtained without using any harsh solvents.
“The majority of Frutarom’s core products are produced using this technology, including: Benolea? (olive leaf), Portusana? (purslane) and Neuravena? (avena/green oat), resulting in ingredients with superior safety and stability,”adds Mr Lind. “The addition of proprietary clinical studies behind these products ensures the best combination of high quality, safety and effective natural ingredients.”